Coronavirus Update: Pfizer Switches To Alternate COVID Vaccine Over T Cell Response
Plus: Yuhan and Abclon Advance Candidate
Executive Summary
Signs that BNT162b2 could be more effective in older age groups led companies to switch lead candidates, and they now head into a pivotal late-stage study.
You may also be interested in...
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
Company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
US Studies Hold The Key To COVID-19 Vaccines Race
US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.